Literature DB >> 24413269

Adaptive reprogramming of the breast cancer kinome.

T J Stuhlmiller1, H S Earp2, G L Johnson1.   

Abstract

Our understanding of cancer has grown considerably with recent advances in high-throughput genome and transcriptome sequencing, but techniques to comprehensively analyze protein activity are still in development. Methods to quantitatively measure the activation of signaling pathways within tumors at baseline and following therapeutic intervention will prove critical to the design of proper treatment regimens. Focusing on breast cancer, we present such a method to understand kinase signaling using multiplexed kinase inhibitor beads coupled with mass spectrometry (MIB/MS).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24413269      PMCID: PMC4091669          DOI: 10.1038/clpt.2014.8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.

Authors:  Marcus Bantscheff; Dirk Eberhard; Yann Abraham; Sonja Bastuck; Markus Boesche; Scott Hobson; Toby Mathieson; Jessica Perrin; Manfred Raida; Christina Rau; Valérie Reader; Gavain Sweetman; Andreas Bauer; Tewis Bouwmeester; Carsten Hopf; Ulrich Kruse; Gitte Neubauer; Nigel Ramsden; Jens Rick; Bernhard Kuster; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

2.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

3.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Authors:  Sarat Chandarlapaty; Ayana Sawai; Maurizio Scaltriti; Vanessa Rodrik-Outmezguine; Olivera Grbovic-Huezo; Violeta Serra; Pradip K Majumder; Jose Baselga; Neal Rosen
Journal:  Cancer Cell       Date:  2011-01-06       Impact factor: 31.743

4.  Outlier kinase expression by RNA sequencing as targets for precision therapy.

Authors:  Vishal Kothari; Iris Wei; Sunita Shankar; Shanker Kalyana-Sundaram; Lidong Wang; Linda W Ma; Pankaj Vats; Catherine S Grasso; Dan R Robinson; Yi-Mi Wu; Xuhong Cao; Diane M Simeone; Arul M Chinnaiyan; Chandan Kumar-Sinha
Journal:  Cancer Discov       Date:  2013-02-05       Impact factor: 39.397

5.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

  5 in total
  13 in total

1.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

2.  Do cells use passwords in cell-state transitions? Is cell signaling sometimes encrypted?

Authors:  Alex Root
Journal:  Theory Biosci       Date:  2019-06-07       Impact factor: 1.919

3.  The butterfly effect in cancer: a single base mutation can remodel the cell.

Authors:  Jonathan R Hart; Yaoyang Zhang; Lujian Liao; Lynn Ueno; Lisa Du; Marloes Jonkers; John R Yates; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

4.  Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK.

Authors:  Lindsey S Treviño; Michael J Bolt; Sandra L Grimm; Dean P Edwards; Michael A Mancini; Nancy L Weigel
Journal:  Mol Endocrinol       Date:  2015-12-11

5.  EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

Authors:  Remi Adelaiye-Ogala; Justin Budka; Nur P Damayanti; Justine Arrington; Mary Ferris; Chuan-Chih Hsu; Sreenivasulu Chintala; Ashley Orillion; Kiersten Marie Miles; Li Shen; May Elbanna; Eric Ciamporcero; Sreevani Arisa; Piergiorgio Pettazzoni; Giulio F Draetta; Mukund Seshadri; Bradley Hancock; Milan Radovich; Janaiah Kota; Michael Buck; Heike Keilhack; Brian P McCarthy; Scott A Persohn; Paul R Territo; Yong Zang; Joseph Irudayaraj; W Andy Tao; Peter Hollenhorst; Roberto Pili
Journal:  Cancer Res       Date:  2017-10-04       Impact factor: 12.701

6.  SOD3 Is a Non-Mutagenic Growth Regulator Affecting Cell Migration and Proliferation Signal Transduction.

Authors:  Alessia Parascandolo; Mikko O Laukkanen
Journal:  Antioxidants (Basel)       Date:  2021-04-21

7.  Characterization of DNA variants in the human kinome in breast cancer.

Authors:  Divyansh Agarwal; Yuan Qi; Tingting Jiang; Xiuping Liu; Weiwei Shi; Vikram B Wali; Benjamin Turk; Jeffrey S Ross; W Fraser Symmans; Lajos Pusztai; Christos Hatzis
Journal:  Sci Rep       Date:  2015-09-30       Impact factor: 4.379

Review 8.  Recent advances in methods to assess the activity of the kinome.

Authors:  Maria Radu; Jonathan Chernoff
Journal:  F1000Res       Date:  2017-06-26

9.  Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

Authors:  Robert S McNeill; Demitra A Canoutas; Timothy J Stuhlmiller; Harshil D Dhruv; David M Irvin; Ryan E Bash; Steven P Angus; Laura E Herring; Jeremy M Simon; Kasey R Skinner; Juanita C Limas; Xin Chen; Ralf S Schmid; Marni B Siegel; Amanda E D Van Swearingen; Michael J Hadler; Erik P Sulman; Jann N Sarkaria; Carey K Anders; Lee M Graves; Michael E Berens; Gary L Johnson; C Ryan Miller
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

10.  Weight loss reduces basal-like breast cancer through kinome reprogramming.

Authors:  Yuanyuan Qin; Sneha Sundaram; Luma Essaid; Xin Chen; Samantha M Miller; Feng Yan; David B Darr; Joseph A Galanko; Stephanie A Montgomery; Michael B Major; Gary L Johnson; Melissa A Troester; Liza Makowski
Journal:  Cancer Cell Int       Date:  2016-04-01       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.